Table 1 Study cohort: patient characteristics age of diagnosis (AoD), year of diagnosis (YoD), molecular subgroup (MSG), somatic copy number aberration (chr17), tumor status and follow up time (death of disease DOD, death of other cause DOC, complete remission CR, and progressive disease PD)
From: High impact of miRNA-4521 on FOXM1 expression in medulloblastoma
Case | Age of diagnosis (years) | Gender | Year of diagnosis | Molecular subtype | 17p loss | 17q gain | Tumor recurrence (yes/no) | Time to recurrence (Month) | Status/follow up in month |
|---|---|---|---|---|---|---|---|---|---|
1 | 11 | F | 2009 | WNT | No | No | Yes | 70 | DOD,71 |
2 | 9 | M | 2005 | WNT | No | No | Yes | 59 | DOD,85 |
3 | 5.5 | M | 2012 | WNT | No | No | No | n/a | CR,71+ |
4 | 1.4 | M | 2008 | SHH | No | No | No | n/a | CR,114+ |
5 | 3 | F | 2007 | SHH | No | No | No | n/a | CR,121+ |
6 | 1 | M | 2000 | SHH | No | No | Yes | 11 | DOD,12 |
7 | 9 | M | 2002 | SHH | Yes | No | Yes | 15 | DOD,15 |
8 | 4 | F | 1998 | Group 3 | Yes | No | Yes | 26 | DOD,67 |
9 | 12 | M | 2006 | Group 3 | No | No | Yes | 31 | DOC,53 |
10 | 3 | F | 2003 | Group 3 | No | No | No | n/a | CR,167+ |
11 | 4.5 | F | 2012 | Group 3 | Yes | Yes | No | n/a | CR,68+ |
12 | 2.5 | F | 2013 | Group 3 | No | No | No | n/a | CR,58+ |
13 | 1.5 | F | 2012 | Group 3 | No | No | Yes | 25 | CR,67+ |
14 | 1 | M | 2014 | Group 3 | Yes | Yes | Yes | 2 | DOD,6 |
15 | 14 | M | 2009 | Group 4 | Yes | Yes | No | n/a | CR,101+ |
16 | 3.5 | M | 2008 | Group 4 | No | Yes | No | n/a | CR,114+ |
17 | 11 | M | 2014 | Group 4 | Yes | Yes | No | n/a | CR,43+ |
18 | 10 | M | 2004 | Group 4 | Yes | Yes | Yes | 41 | CR,157+ |
19 | 5 | M | 2004 | Group 4 | No | Yes | No | n/a | CR,165+ |
20 | 7.5 | M | 2013 | Group 4 | Yes | Yes | Yes | 25 | CR,58+ |
21 | 8 | F | 2013 | Group 4 | Yes | Yes | Yes | 21 | PD,53+ |
22 | 11.5 | M | 2008 | Group 4 | Yes | Yes | Yes | 37 | CR,117+ |
